Sagimet Biosciences Inc. (NASDAQ: SGMT) Stock Information | RedChip

Sagimet Biosciences Inc. (NASDAQ: SGMT) Listen to this Section


$2.75
-0.0100 ( -0.36% ) 250.1K

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Market Data


Open


$2.75

Previous close


$2.76

Volume


250.1K

Market cap


$87.76M

Day range


$2.70 - $2.87

52 week range


$2.13 - $20.71

Insider Ownership Transactions

Total Amount Purchased: -4,980,388.00 | $ -13,696,067.00

Date Type Amount Purchased Purchaser
2024-06-07 Sale -9279.00 Hoelscher Paul W.
2024-05-08 Sale -587181.00 Chauche Thierry
2024-04-03 Sale -73014.00 Walbert Timothy P
2024-04-03 Sale -73014.00 Hoelscher Paul W.
2024-03-28 Buy 12100.00 Happel David
2024-01-31 Sale -850000.00 NEW ENTERPRISE ASSOCIATES 13 LP
2024-01-31 Sale -850000.00 SANDELL SCOTT D
2024-01-31 Sale -850000.00 BASKETT FOREST
2024-01-31 Sale -850000.00 NEA Partners 13, Limited Partnership
2024-01-31 Sale -850000.00 KERINS PATRICK J

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Jul 23, 2024
8-k 8K-related 48 Jul 02, 2024
8-k/a 8K-related 15 Jun 13, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024
8-k 8K-related 15 Jun 06, 2024
8-k 8K-related 47 May 23, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.